Regenxbio (NASDAQ:RGNX) Upgraded by TheStreet to C-

TheStreet upgraded shares of Regenxbio (NASDAQ:RGNX) from a d+ rating to a c- rating in a report released on Tuesday morning, TheStreetRatingsTable reports.

Several other equities research analysts have also commented on RGNX. Chardan Capital reiterated a buy rating and issued a $150.00 price objective on shares of Regenxbio in a research note on Wednesday, January 29th. Evercore ISI reiterated a buy rating and issued a $65.00 price objective on shares of Regenxbio in a research note on Monday, November 11th. Zacks Investment Research lowered shares of Regenxbio from a hold rating to a sell rating in a research note on Wednesday, February 5th. Morgan Stanley increased their price objective on shares of Regenxbio from $55.00 to $58.00 and gave the company an overweight rating in a research note on Friday, January 17th. Finally, BidaskClub upgraded shares of Regenxbio from a buy rating to a strong-buy rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $71.00.

NASDAQ:RGNX opened at $53.80 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.49 and a current ratio of 11.49. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -30.57 and a beta of 0.83. Regenxbio has a 52 week low of $30.38 and a 52 week high of $63.21. The firm has a 50-day moving average price of $45.23 and a two-hundred day moving average price of $40.27.

In other news, Director Donald J. Hayden, Jr. sold 3,200 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $50.01, for a total transaction of $160,032.00. Following the completion of the transaction, the director now directly owns 3,200 shares of the company’s stock, valued at approximately $160,032. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 30,000 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $45.60, for a total transaction of $1,368,000.00. Following the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $1,368,000. The disclosure for this sale can be found here. Insiders have sold a total of 49,016 shares of company stock valued at $2,256,957 over the last three months. Insiders own 13.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Chevy Chase Trust Holdings Inc. bought a new position in shares of Regenxbio during the 4th quarter valued at approximately $41,000. Advisor Group Inc. boosted its holdings in Regenxbio by 342.0% in the 4th quarter. Advisor Group Inc. now owns 1,158 shares of the biotechnology company’s stock worth $47,000 after buying an additional 896 shares during the period. IFP Advisors Inc boosted its holdings in Regenxbio by 532.0% in the 4th quarter. IFP Advisors Inc now owns 1,264 shares of the biotechnology company’s stock worth $52,000 after buying an additional 1,064 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Regenxbio by 169.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,760 shares of the biotechnology company’s stock worth $73,000 after buying an additional 1,106 shares during the period. Finally, Tower Research Capital LLC TRC bought a new position in Regenxbio in the 4th quarter worth approximately $99,000. 78.43% of the stock is owned by hedge funds and other institutional investors.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

See Also: What is meant by buying and selling pressure?

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.